Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study

OBJECTIVES: To evaluate the preliminary efficacy and safety of Pueraria mirifica in the treatment of vasomotor symptoms. DESIGN: Open-label study. SETTING: Hat Yai Regional Hospital, Thailand. SUBJECTS: Pre and postmenopausal women with vasomotor symptoms, such as hot flushes and night sweats. Other unpleasant symptoms, urogenital and psychological symptoms, were also evaluated. MATERIAL AND METHOD: Patients were enrolled voluntarily and randomly received 50 mg or 100 mg of Pueraria mirifica in capsules, once daily for six months. RESULTS: Thirty-seven cases were evaluated. 20 of 37 (54.1%) randomly received a dose of 50 mg/day of Pueraria mirifica (Group A), and 17 of 37 (45.9%) received 100 mg/day of Pueraria mirifica (Group B). CONCLUSIONS: Pueraria mirifica, containing phytoestrogens, relatively alleviated the climacteric symptoms in perimenopausal women. While there was a slight decrease in Iipoproteins and an increase in hormonal profiles, Pueraria mirifica demonstrates great promise in the treatment of climacteric symptoms among perimenopausal women.

Lamlertkittikul Surachai; Chandeying Verapol Department of Obstetrics and Gynecology, Hat Yai Regional Hospital, Songkhla 90110, Thailand Journal of the Medical Association of Thailand = Chotmaihet thangphaet (2004), 87(1), 33-40. Journal code: 7507216. ISSN:0125-2208. (CLINICAL TRIAL); (CLINICAL TRIAL, PHASE II); Journal; Article; (JOURNAL ARTICLE); (RANDOMIZED CONTROLLED TRIAL); (RESEARCH SUPPORT, NON-U.S. GOV’T) written in English. PubMed ID 14971532 AN 2004081982 MEDLINE (Copyright (C) 2009 US. National Library of Medicine on SciFinder (R))

Full Research (PDF): Click here